1:1 Bonus Share: Healthcare stock in focus after board sets record date for bonus issue
Synopsis: Dr. Lal PathLabs will issue a 1:1 bonus share for shareholders on the record date December 19, 2025, with allotment on December 22, 2025, aiming to reward investors and improve share liquidity. This is a leading Indian diagnostic services company with a nationwide integrated network, offering a wide range of tests for disease diagnosis, […] The post 1:1 Bonus Share: Healthcare stock in focus after board sets record date for bonus issue appeared first on Trade Brains.
Synopsis: Dr. Lal PathLabs will issue a 1:1 bonus share for shareholders on the record date December 19, 2025, with allotment on December 22, 2025, aiming to reward investors and improve share liquidity.
This is a leading Indian diagnostic services company with a nationwide integrated network, offering a wide range of tests for disease diagnosis, prevention, monitoring, and treatment is now in the spotlight after the company announces record date for bonus issue.
With market capitalization of Rs. 23,943 cr, the shares of Dr. Lal PathLabs Ltd are currently trading at Rs. 2,858 per share, down from its previous close of Rs. 2,872.90 per share.
Record date
Dr. Lal PathLabs Limited has informed the stock exchanges that its Board of Directors has fixed Friday, December 19, 2025, as the record date for determining shareholders eligible for its 1:1 bonus equity share issue, as earlier approved by the company’s members.
Under this bonus issue, eligible shareholders will receive one fully paid-up equity share of face value Rs. 10 for every one existing equity share held as on the record date, based on records from NSDL and CDSL.
The company has further clarified that, in line with SEBI guidelines, the deemed date of allotment for the bonus shares will be Monday, December 22, 2025. This move aims to reward shareholders by enhancing liquidity while maintaining the company’s capital structure.
About the company
Dr. Lal PathLabs Limited is one of India’s leading diagnostics and pathology service providers, offering a wide range of laboratory tests, preventive health check-ups, and diagnostic services.The company operates a nationwide network of laboratories and collection centers, serving patients, hospitals, and clinicians with a strong focus on quality, accuracy, and technology-driven healthcare solutions.
It demonstrates strong financial health with a ROCE of 28.9% and ROE of 24.3%, supported by a very low debt-to-equity ratio of 0.07, indicating robust profitability and minimal leverage.
On a YoY basis, sales grew 11% to Rs. 731 cr from Rs. 660 cr in Q2FY25, EBITDA increased 11% to Rs. 224 cr, and net profit rose 16% to Rs. 152 cr. EPS also improved 16% to Rs. 17.95.
Written by Manideep Appana
Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post 1:1 Bonus Share: Healthcare stock in focus after board sets record date for bonus issue appeared first on Trade Brains.
What's Your Reaction?

